Primary stroke prevention and hypertension treatment: which is the first-line strategy?

Roberta Ravenni,1 Joe F. Jabre,2 Edoardo Casiglia3 Alberto Mazza4
1Department of Neuroscience, Santa Maria della Misericordia Hospital, Rovigo, Italy; 2Department of Neurology, Boston University School of Medicine, Massachusetts, USA; 3Department of Clinical and Experimental Medicine, University of Padova; 4Department of Internal Medicine, Santa Maria della Misericordia Hospital, Rovigo, Italy

Abstract

Hypertension (HT) is considered the main classic vascular risk factor for stroke and the importance of lowering blood pressure (BP) is well established. However, not all the benefit of antihypertensive treatment is due to BP reduction per se, as the effect of reducing the risk of stroke differs among classes of antihypertensive agents. Extensive evidences support that angiotensin-converting enzyme inhibitors (ACEI), angiotensin II receptor blockers (ARB), dihydropyridine calcium channel blockers (CCB) and thiazide diuretics each reduced risk of stroke compared with placebo or no treatment. Therefore, when combination therapy is required, a combination of these antihypertensive classes represents a logical approach. Despite the efficacy of antihypertensive therapy a large proportion of the population, still has undiagnosed or inadequately treated HT, and remain at high risk of stroke. In primary stroke prevention current guidelines recommend a systolic/diastolic BP goal of <140/<90 mmHg in the general population and <130/80 mmHg in diabetics and in subjects with high cardiovascular risk and renal disease. The recent release in the market of the fixed-dose combination (FDC) of ACEI or ARB and CCB should provide a better control of BP. However to confirm the efficacy of the FDC in primary stroke prevention, clinical intervention trials are needed.

Introduction

Stroke is a leading cause of death and disability worldwide, exacting an enormous financial toll.1 The total incidence of stroke is expected to increase considerably over the next two decades particularly in European Union where the estimated number of stroke events will increase to 1,500,000 by 2025.2 Among the risk factors for stroke, epidemiological studies carried out in the past decades have definitely established that arterial hypertension (HT) is the main risk factor for stroke,3,4 and that its disabling complications are directly associated to the severity of blood pressure (BP) increase.5 However, other evidences have been outlined that the risk of stroke associated with high BP values is not irreversible, as the risk of stroke incidence could be strongly reduced if BP values were controlled by and optimal anti-hypertensive treatment.6 The latter is fundamental for stroke prevention as the early discontinuation of the anti-hypertensive treatment is associated with a 30% increase in risk of stroke.7 In this respect all anti-hypertensive drugs classes may be useful in preventing stroke, but some of these may exert a cerebrovascular protection independently to their BP reduction.8

This paper reviews the role of HT as a risk factor for stroke, provides an update on which is the antihypertensive treatment recommended in primary stroke prevention and explores the potential efficacy of fixed-dose combination therapy in preventing stroke.

Hypertension and risk of stroke

Approximately 54% of strokes can be attributed worldwide to high BP values in both gender and in all ages.4 As a consequence, hypertensive subjects are 3 to 4 times more likely to have a stroke than the normotensives.8 In particular, it was established that a 2 mmHg rise in systolic BP in middle life is associated with 10% increase in risk of stroke.9 In addition the relationship between BP and risk of first stroke is direct, continuous and independent, with the risk increasing continuously above a BP of 115/75 mmHg.2

Among BP components, many researchers have established a different role of systolic and diastolic on cerebrovascular risk, especially when diastolic is associated with high systolic levels. This association determines an increase of the pulsatile component of BP (pulse pressure, PP). The increase of PP is low systolic levels be associated with a strong benefit for stroke prevention.

Blood pressure targets to achieve in primary stroke prevention

Despite the overwhelming evidence that HT represents the first risk factor for stroke and that the cerebrovascular benefits the most from BP lowering, no randomized clinical trials provided a BP target for effective primary prevention of stroke.10 Current international guidelines recommend a systolic/diastolic goal of <140/<90 mmHg in the general population and <130/<80 mmHg in diabetic subjects and in those with renal disease.11,12 Whether a lower target has further benefits in primary disease.13 Large-scale placebo-controlled clinical trials have demonstrated the efficacy on stroke prevention of treating elderly with ISH.14,15 However the studies of Langer et al.16 and of Benetos et al.17 showed higher stroke mortality in treated hypertensives having a prevalent decrease in diastolic. Low diastolic levels have been associated with increased coronary events, a phenomenon known as the J-curve effect.18 Interestingly, this relationship was not observed for stroke and was not present among patients who had undergone coronary revascularization.19 In contrast to the heart, the brain is very infrequently subjected to J-curve effect as the brain’s blood flow auto-regulation depends mostly on systolic BP.20 This was confirmed by the results of the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study (ONTARGET), where no J-curve pattern did appear for stroke.21 For the latter the assumption the lower the systolic BP, the lower the risk was correct, and it was confirmed in a meta-analysis by Staessen et al.22 who found in treated and untreated elderly patients with ISH low systolic levels be associated with a strong benefit for stroke prevention.

Keywords: antihypertensive therapy, hypertension, prevention, renin angiotensin system, stroke.

Accepted for publication: 30 August 2011. Revision received: 10 August 2011. Accepted for publication: 30 August 2011.

This work is licensed under a Creative Commons Attribution NonCommercial 3.0 License (CC BY-NC 3.0).

©Copyright R. Ravenni et al., 2011
License PAGEPress, Italy
Neurology International 2011; 3:e12
doi:10.4081/ni.2011.e12
stroke prevention is uncertain. Although in a meta-analysis comparing trials with more-intensive than those with less-intensive targets of BP found a 23% reduced risk of stroke in the former than in the latter, the target <140/<90 mmHg was not achieved. In the HOT study there was no difference in rates of stroke among groups of hypertensive patients who achieved mean diastolic values of 85.2, 83.2 or 81.1 mmHg. For ISH, no trial has been performed. Finally, the investigators of the HYVET trial provided evidence that antihypertensive treatment is beneficial also in the elderly and in very elderly subjects (>80 years of age); the latter a group excluded from most other trials of antihypertensive therapy. The primary end point of HYVET was fatal or nonfatal stroke. At two years of follow-up, active treatment was associated with a 30% reduction in the rate of all strokes and a 39% reduction in the rate of death from fatal stroke. The greater reduction of risk was observed for a BP target of <120/<80 mmHg in treated patients over age 80, but the efficacy of further reductions in BP needs to be established.

What are the available evidences with renin angiotensin system blockade?

In the hypertensives, the renin angiotensin system (RAS) has been linked to the risk of stroke. Therefore, it has been suggested that RAS blockade would provide a neuroprotective effect. In the literature studies with ACEI have produced different results in primary stroke prevention. In the Heart Outcomes Prevention Evaluation (HOPE) study, ramipril reduced all stroke by 32% and fatal stroke by 61% compared with placebo. On the contrary, in the Captopril Prevention Project, fatal and nonfatal strokes were found to be more frequent in patients randomized to captopril than to conventional therapy. In the ALLHAT, lisinopril was less effective in preventing stroke than diuretic therapy. As a consequence, the common belief in that in clinical practice ACEI in primary stroke prevention it has yet to be fully confirmed. On the other hand, it has been well established that the inhibition of the negative effects of angiotensin in the cerebral circulation by ARB, determines a neuroprotective effect through the over activation of the AT2 receptors (see below). This observation comes from large clinical trials. In the LIFE study, that enrolled hypertensive patients with left ventricular hypertrophy, losartan significantly reduced the rate of fatal and nonfatal stroke by 25%. In the SCOPE, candesartan-based treatment reduced non-fatal stroke by 30% and all stroke by 24% compared with placebo in elderly subjects. In the JIKEI Heart study, the HTs receiving valsartan had a significant reduction of stroke risk when compared with those not taking ARB. Valsartan and other ARB appear to reduce the risk of stroke more than placebo in primary stroke prevention. This result was also confirmed in a meta-analysis of about 50,000 patients, where treatment with ARB were associated with a significant reduction of stroke risk (~8%) compared with ACEI. In conclusion the cerebrovascular benefits of ARB seem to be class-related rather than drug-related and in general all ARB might be used in primary stroke prevention.

Are there evidences with CCB?

Different studies have compared the effects of CCB vs. placebo or an active treatment for preventing stroke events. In particular, nitrendipine-based treatment reduced the incidence of fatal and nonfatal stroke by 38%. In the ACTION study, nifedipine GITS reduced the risk of any stroke or TIA by 30% compared with placebo in hypertensive patients with high cardiovascular risk. CCB have also been shown to provide better protection against fatal and nonfatal stroke than older drugs, such as β-blockers, diuretics and ACEI. This has particularly been observed in a meta-analysis involving 4 trials, where CCB have been shown to provide benefit compared to ACEI. In the ASCOT study,amlodipine reduced fatal and nonfatal stroke better than atenolol (+23%). Moreover, the risk of stroke with amlodipine was statistically less when compared with non-ARB antihypertensive drugs and with ARB therapies separately.

What are the available evidences with diuretics?

In the literature, it is well known that diuretic therapy, particularly thiazide diuretics, reduced the risk of stroke compared to placebo or to no antihypertensive treatment. This has particularly been observed in the elderly with ISH. In the Systolic Hypertension in the Elderly Program (SHEP) chlorthalidone caused a 36% reduction in the incidence of stroke. The SHEP documented that the benefit of BP lowering therapy is maintained also in very elderly hypertensives aged ≥80 years. Another meta-analysis found that diuretic therapy was superior to ACEI therapy, particularly in blacks. However, because of their lower tolerance and efficacy on regression of target organ damage compared with ARB, ACEI and CCB, in clinical practice diuretics are rarely used alone as first-line treatment for primary stroke prevention.

What is the mechanism of modulation of stroke by renin angiotensin system blockade and CCB?

Lowering BP is per se the most important determinant of stroke risk reduction. This has particularly been observed with CCB. However this benefit appears in part independent of BP lowering. The same result were been found with ARB, suggesting that these agents also have some BP-independent benefits. In experimental animal models, pre-treatment with an ARB at a sub-antihypertensive dose was more effective than an ACEI for reducing infarct size and neurological deficits following transient focal ischemia.

The mechanisms by which CCB and ARB prevent stroke beyond BP reductions is unknown, although it is common belief that these antihypertensive drugs promote their protective action on stroke by reducing the progression towards the vascular and cardiac organ damage associated with hypertension.

The increase of carotid intima-media thickness (IMT) is an independent risk factor of stroke and it is well established that - despite comparable reductions in BP - CCB reduce IMT more than ACEI do. This has particularly been observed in the INSIGHT study, where the hypertensives receiving nifedipine gastrointestinal-transport-system (GITS) had greater regression of IMT than those taking diuretic.

In the same manner, ARB reduce IMT more than atenolol despite a similar effect on BP, an effect that seems to be mediated by improvements in nitric oxide production and decreases in oxidative stress. Changes in central aortic pressure but not in peripheral BP could explain some differences between CCB and other antihypertensive drugs. In the CAFE study, despite comparable brachial pressures, amlodipine-based treatment reduced central systolic BP more than atenolol. It has been suggested that heart rate is a major determinant of the difference between central and brachial BP and might account for the less effective lowering of central BP with atenolol. As a consequence, in the CAFE study the effect on central BP and heart rate could explain some of the differences in stroke incidence between atenolol and amlodipine.

The increase of left ventricular mass is an independent risk factor for stroke. In a meta-analysis, CCB and ARB were reported to reduce left ventricular mass index by 11% and 13%, respectively.

There is evidence that antihypertensive treatment with ARB and ACEI prevents new-onset of non-valvular atrial fibrillation, a condition that is common in the hypertensives and associated with 5-fold increased risk of embolic stroke. However, because of their lower tolerance and efficacy on regression of target organ damage compared with ARB, ACEI and CCB, in clinical practice diuretics are rarely used alone as first-line treatment for primary stroke prevention.
Potential benefit of fixed-dose combination therapy

Despite the availability of a wide range of antihypertensive agents, almost two-thirds of the hypertensives fail to achieve the BP goals recommended by current ESH/ESC hypertension guidelines and have poorly controlled BP. As a consequence, they remain at a high risk of morbidity and stroke and require effective treatment options. Sub-optimal BP control is often due to poor patient compliance and results in a significant health and economic burden. Numerous clinical trials have shown that most patients require at least two antihypertensive agents to achieve adequate BP control and associated significant reductions in stroke morbidity and mortality. Combination therapy using two drugs with different mechanisms of action achieves better efficacy and tolerability outcomes than treatment with either component drug alone. Furthermore, when this combination is administered as a fixed-dose combination, other benefits are achieved, such as an improved compliance and potentially lower costs of treatment. The good efficacy and tolerability of the fixed-dose of a CCB with an ACEI or an ARB is well established, and this combination is recommended in the reappraisal of the ESH/ESC guidelines as a first choice in high-risk hypertensive patients. In clinical trials the fixed-dose combination improves BP to a greater extent than either drug as monotherapy and, when compared with antihypertensive mono-therapies, it may also offer equivalent or better efficacy and the same or improved tolerability. Therefore, fixed-dose combination has the potential to reduce both the risk of stroke and the non-drug healthcare costs associated with HT.

Direct neuroprotective benefit of the antihypertensive agents

As mentioned above, RAS blockade seems to determine a direct neuroprotective effect. This is particularly true for ARB, as it has been observed that angiotensin II induces cerebrovascular hypertrophy and remodelling, inhibits endothelium-dependent relaxation and disrupts the blood-brain barrier. Two types of angiotensin II receptors have been implicated to explain this benefit. Type 1 receptors, expressed in different tissues, induce vasoconstriction, sodium and water retention, smooth-muscle proliferation, and vascular endothelial damage, while type 2 receptors, expressed in fetal tissues and up-regulated in ischemic brain tissue, modulate the type 1 receptor activity reducing inflammation and neuronal apoptosis and inducing vasodilation, thereby mediating neuroprotective effect.

There is some evidence that ARB may provide greater reduction in the risk of stroke than diuretics, long-acting dihydropyridine CCB, ACEI and β-blockers despite similar reduction in BP. This evidence has particularly been demonstrated with losartan vs. atenolol, candesartan vs. hydrochlorothiazide and eprosartan vs. nitrendipine in clinical studies where the risk of stroke was low. However, the ONTARGET study was unable to show a significant reduction in stroke with valsartan than ramipril. In addition, CCB and ARB seem to have BP-independent effects on stroke in animal models, probably via a reduction of inflammation in cerebral microvessels, protection of cerebral circulation (improving of cerebral blood flow auto-regulation) and reduction of superoxide production. However, these data should be cautiously translated to humans, where these mechanisms have not been readily observed.

Conclusions

Hypertension remains the most important established and modifiable classic vascular risk factor for stroke, and antihypertensive treatment the most effective strategy for preventing stroke as well as other BP-related target organ damage. Reduction in BP is generally more important than the choice of specific agents, but some classes of antihypertensives offer direct neuroprotective benefit: those acting on RAS blockade, CCB and thiazide diuretics represent the three classes with the strongest effect in primary stroke prevention. The use of fixed-dose combination of these drugs may increase patient compliance and persistence to antihypertensive treatment. However further studies are required to evaluate the neuroprotective effect of FDC therapy in primary stroke prevention.

References

1. Tu JV. Reducing the global burden of stroke: INTERSTROKE. Lancet 2010;376:74-5.
2. Truelsen T, Piechowski-Jó wiak B, Bonita R, et al. Stroke incidence and prevalence in Europe: a review of available data. Eur J Neurol 2006;13:581-98.
3. D’Agostino RB, Wolf PA, Belanger AJ, Kannel WB. Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study. Stroke 1994;25:40-3.
4. Lawes CM, Vander Hoorn S, Rodgers A. International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet 2008;371:1513-8.
5. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Prospective Studies Collaboration. Lancet 2002;360:1903-13.
6. Grassi G, Quarti-Trevano F, Dell’oro R, Mancia G. Antihypertensive treatment and stroke prevention: from recent meta-analyses to the PROFESS trial. Curr Hypertens Rep 2009;11:265-70.
7. Breekveldt-Postma NS, Penning-van Beest FJ, Siisikonen SJ, et al. The effect of discontinuation of antihypertensives on the risk of acute myocardial infarction and stroke. Curr Med Res Opin 2008;24:121-7.
8. Gorelick PB. New horizons for stroke prevention: PROGRESS and HOPE. Lancet Neurol 2002;1:149-56.
9. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;14; 360:1903-13.
10. Safar ME. Pulse pressure in essential hypertension: a haemodynamic study. J Hypertens 1987;5:213-18.
11. Benetos A, Laurent S, Asmar RG, Lacolley P. Large artery stiffness in hypertension. J Hypertens 1997;15:589-97.
12. Sutton-Tyrrell K, Alcorn HG, Wolfson SK et al. Predictors of carotid stenosis in older adults with and without isolated systolic hypertension. Stroke 1993;24:355-61.
13. Suurkula M, Agewall S, Fagerberg B, et al. Ultrasound evaluation of atherosclerotic manifestations in the carotid artery in high-risk hypertensive patients. Risk Intervention Study (RIS) Group. Arterioscler Thromb 1994;14:1297-304.
14. Millar JA, Lever AF, Burke V. Pulse pressure as a risk factor for cardiovascular events in the MRC Mild Hypertension trial. J Hypertens 1999;17:1065-72.
15. Lee ML, Rosner BA, Weiss ST. Relationship of blood pressure to cardiovascular death: the effects of pulse pressure in the elderly. Ann Epidemiol 1999;9:101-7.
16. Voko Z, Bots ML, Hofman A, et al. J-shaped relation between blood pressure and stroke in treated hypertensives. Hypertension 1999;34:1181-5.
17. Selmer R. Blood pressure and twenty-year mortality in the city of Bergen, Norway. Am J Epidemiol 1992;136:428-40.
18. Mazz A, Pessina AC, Gianiucu P, et al. Pulse pressure: an independent predictor of coronary and stroke mortality in elderly females from the general population. Blood Press 2001;10:205-11.
19. Domanski MJ, Davis BR, Pfeffer MA, et al. Isolated systolic hypertension: prognostic information provided by pulse pressure. Hypertension 1999;34:375-80.

[Neurology International 2011; 3:e12] [page 47]
20. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3255-64.

21. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment in older patients with isolated systolic hypertension. Lancet 1997;350:757-64.

22. Dahlof B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991;338:1281-5.

23. Langer RD, Gianiats TG, Barrett-Conner E. Paradoxic survival of elderly men with high blood pressure. Br Med J 1989;298:1356-7.

24. Benetos A, Zureik M, Morcet J, et al. Decrease in diastolic blood pressure combined with an increase in systolic blood pressure is associated with a higher cardiovascular mortality in men. J Am Coll Cardiol 2000;35:673-80.

25. Stewart IM. Relation of reduction in pressure to first myocardial infarction in patients receiving treatment for severe hypertension. Lancet 1979;1:861-5.

26. Bengale S, Messerli FH, Wen CC, et al. J curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. Eur Heart J 2010;31:2897-908.

27. Chrysant SG. Current status of aggressive blood pressure control. World J Cardiol 2011;3:65-71.

28. ONTARGET Investigators, Yusuf S, Teo KK, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59.

29. Staessen JA, Gasowski J, Wang JG, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2009;355:865-72.

30. Gorelick PB. Challenges of designing trials for the primary prevention of stroke. Stroke 2009;40 Suppl 3:S82-4.

31. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009;27:2121-58.

32. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72.

33. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527-35.

34. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intense blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755-62.

35. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358:1897-98.

36. Iadecola C, Gorelick PB. Hypertension, angiotensin, and stroke: beyond blood pressure. Stroke 2004;35:348-50.

37. Schrader J, Kuilschenki A, Dendorfer A. Inhibition of the renin-angiotensin system and the prevention of stroke. Am J Cardiovasc Drugs 2007;7:25-37.

38. Bosch J, Yusuf S, Pogue J, et al. Heart outcomes prevention evaluation. Use of ramipril in preventing stroke: double-blind randomised trial. BMJ 2002;324:699-702.

39. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999;353:611-6.

40. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.

41. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.

42. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875-86.

43. Mochizuki S, Dahlöf B, Shimizu M, et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007;369:1431-9.

44. Reboldi G, Angeli F, Cavallini C, et al. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. J Hypertens 2008;26:1282-9.

45. Pitt B, Byington RP, Furberg CD, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000;102:1503-10.

46. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997;350:757-64.

47. Staessen JA, Thijs L, Fagard RH, et al. Calcium channel blockade and cardiovascular prognosis in the European trial on isolated systolic hypertension. Hypertension 1998;32:410-6.

48. Wang JG, Staessen JA, Gong L, Liu L. Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group. Arch Intern Med 2000;160:211-20.

49. Lubsen J, Wagener G, Kirwan BA, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial. J Hypertens 2005;23:641-8.

50. Bangalore S, Messerli FH. A review of stroke in patients with hypertension and coronary artery disease: Focus on calcium channel blockers. Int J Clin Pract 2006;60:1281-6.

51. Staessen JA, Li Y, Thijs L, Wang JG. Blood pressure reduction and cardiovascular prevention: an update including the 2003–2004 secondary prevention trials. Hypertens Res 2005;28:385-407.

52. Lawes CM, Bennett DA, Feigin VL, Rodgers A. Blood pressure and stroke: an overview of published reviews. Stroke 2004;35:1024-33.

53. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required vs atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906.

54. Wang JG, Li Y, Franklin SS, Safar M. Prevention of stroke and myocardial infarction by amlodipine and angiotensin receptor blockers. A quantitative overview. Hypertension 2007;50:181-8.

55. Wright JM, Musini VM. First-line drugs for hypertension. Cochrane Database Syst Rev 2009;CD001841.

56. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative...
patients when compared with atenolol: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) study. J Intern Med 2007;261:472-9.
67. Olsen MH, Wachtell K, Neland K, et al. Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE sub-study. Blood Press 2005;14:177-83.
68. Williams B, Lacy PS, Thom SM, et al. CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006;113:1213-25.
69. Lacy PS, Williams B. Impact of heart rate on the differential impact of blood pressure-lowering drugs on central and peripheral pressures: Data from the Conduit Artery Function Evaluation (CAFE) study. J Hypertens 2008;26 Suppl 1:S459.
70. Klingbeil AU, Schneider M, Martus P, et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003;115:41-6.
71. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology 2007;69:546-54.
72. Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blocker reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005;45:712-9.
73. Madrid AH, Bueno MG, Rebollo JM, et al. Use of irbesartan to maintain sinus rhythm in patients with longstanding persistent atrial fibrillation: a prospective and randomized study. Circulation 2002;106:331-36.
74. Maggioni AP, Latini R, Carson PE, et al. Val-HeFT Investigators. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005;149:548-57.
75. Ducharme A, Swedberg K, Pfeffer MA, et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006;151:985-91.
76. Fitzmaurice DA, Hobbs FD, Jowett S, et al. Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial. BMJ 2007;335:383.
77. Fournier A, Messerli FH, Achard JM, Fernandez L. Cerebroprotection mediated by angiotensin II: A hypothesis supported by recent randomized clinical trials. J Am Coll Cardiol 2004;43:1543-7.
78. Pedelty L, Gorelick PB. Management of hypertension and cerebrovascular disease in the elderly. Am J Med 2008;121(8 suppl):S23-S31.
79. Boutitie F, Optrius R, Achard JM, et al. Does a change in angiotensin II formation caused by antihypertensive drugs affect the risk of stroke? A meta-analysis of trials according to treatment with potentially different effects on angiotensin II. J Hypertens 2007;25:1543-53.
80. Schrader J, Luders S, Kulschewski A, et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: Principal results of a prospective randomized controlled study (MOSES). Stroke 2005;36:1218-26.
81. Ando H, Zhou J, Macova M, et al. Angiotensin II AT1 receptor blockade reverses pathological hypertrophy and inflammation in brain microvessels of spontaneously hypertensive rats. Stroke 2004;35:1726-31.
82. Kumai Y, Ooboshi H, Ago T, et al. Protective effects of angiotensin II type 1 receptor blocker on cerebral circulation independent of blood pressure. Exp Neurol 2008;210:441-8.
83. Talbert RL. Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention. J Am Pharm Assoc 2010;50:e116-25.